Biotech Replimune Faces Derivative Suit Over Trial Claims
By Emilie Ruscoe · August 20, 2025, 3:28 PM EDT
Executives and directors of biotechnology company Replimune Group Inc. face shareholder derivative claims that they concealed issues affecting a clinical trial of one of the company's lead immunotherapy candidates....
To view the full article, register now.